Plasminogen activator inhibitor 1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer

British Journal of Cancer

Volumn 76, Issue 4, 1997, Pages 537-540

  Pierga, J Y ^a   Laine Bidron C ^a   Beuzeboc, P ^a   De Cremoux P ^a   Pouillart, P ^a   Magdelenat H ^a  

^a INSTITUT CURIE   (France)

Author keywords

Breast cancer; Neoadjuvant chemotherapy; Plasminogen activator inhibitor I; S phase fraction

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CELL CYCLE S PHASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PLOIDY; PRIORITY JOURNAL; TUMOR BIOPSY;

EID: 0030743017     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.421     Document Type: Article

References (24)

1. Bloom HJ and Richardson WW (1957) Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer, 11: 359-377
2. Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, Bartoli C, Coopmans De Yoldi GF, Zucali R, Rilke F, Andreola S, Sivestrini R, Di Fronzo G and Valagussa P (1990) Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82: 1539-1545
3. Bouchet C, Spyratos F, Martin PM, Hacène K, Gentile A and Oglobine J (1994) Prognostic value of urokinase-type plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 69: 398-405
4. Chevillard S, Pouillart P, Beldjord C, Asselain B, Beuzeboc P, Magdelénat H and Vielh P (1996) Sequential assessment of MDR phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 77: 292-300
5. Clark GM (1994) Do we really need prognostic factors for breast cancer. Breast Cancer Res Treat 30: 117-126
6. Duffy MJ (1996) Proteases as prognostic markers in cancer. Clin Cancer Res 2: 613-618
7. Fernö M, Baldetorp B, Borg A, Broiullet JP, Olsson H, Rochefort H, Sellberg G, Sigurdsson H and Killander D (1994) Cathepsin D, both a prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer. Eur J Cancer 30A: 2042-2048
8. Foekens JA, Look MP, Peters HA, Van Putten WLJ, Portengen H and Klijn JGM (1995) Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 87: 751-756
9. Grondahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Dano K and Blichert-Toft M (1993) High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521
10. Hedley DW, Clark GM, Cornelisse CJ, Killander D, Kute T and Merkel D (1993) Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Cytometry 14: 482-485
11. Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, Graeff H (1993) Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24: 195-208
12. Magdelénat H (1983) Forage-biopsie et cytoponction pour la détermination des récepteurs hormonaux. Pathologie Biologie 31: 755-760
13. Morrow CS and Cowan KH (1993) Antineoplastic drug-resistance and breast cancer. Ann NY Acad Sci 698: 289-312
14. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M and Henderson IC (1994) C-erbB-2 expression and response to adjuvant therapy in women with node positive early breast cancer. N Engl J Med 330: 1260-1266
15. Namer M, Ramaioli A, Fontana X, Etienne MC, Héry M, Jourlait A, Milano G, Frenay M, François E and Lapalus F (1991) Prognostic value of total cathepsin D in breast tumors. Breast Cancer Res Treat 19: 85-93
16. Remvikos Y (1993) Prognostic value of the S-phase fraction of breast cancer. Br J Cancer 68: 433-434
17. Remvikos Y, Beuzeboc P, Zajdela A, Voillemot N, Magdelénat H and Pouillart P (1989) Correlation of pretreatment proliferate activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst 81: 1383-1387
18. Remvikos Y, Vielh P, Padoy E, Benyahia B, Voillemot N and Magdelénat H (1991) Breast cancer proliferation measured on cytological samples: a study by flow cytometry of S-phase fractions and BrdU incorporation. Br J Cancer 64: 501-507
19. Remvikos Y, Jouve M, Beuzeboc P, Viehl P, Magdelénat H and Pouillart P (1993) Cell cycle modifications of breast cancers during neoadjuvant chemotherapy: a flow cytometry study on fine needle aspirates. Eur J Cancer 29A: 1843-1848
20. Rochefort H (1992) Cathepsin D in breast cancer: a tissue marker associated with metastasis. Eur J Cancer 28A: 1780-1783
21. Romain S, Spyratos F, Lainé-Bidron C, Bouchet C, Guirou O, Martin PM, Oglobine J and Magdelénat H (1995) Comparative study of four extraction procedures for urokinase plasminogen activator and plaminogen activator inhibitor-1 in breast cancer tissues. Eur J Clin Chem Clin Biochem 33: 603-608
22. Scholl SM, Fourquet A, Asselain B, Pierga JY, Vilcoq J, Durand JC, Dorval T, Palangié T, Jouve M, Beuzeboc P, Garcia-Giralt E, Salmon RJ, De La Rochefordière A, Campana F and Pouillart P (1994) Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 30A: 645-652
23. Scholl SM, Pierga JY, Asselain B, Beuzeboc P, Dorval T, Garcia-Giralt E, Jouve M, Palangié T, Remvikos Y, Durand JC, Fourquet A and Pouillart P (1995) Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 31A: 1969-1975
24. Zajdela A, Zillhart P and Voillemot N (1987) Cytological diagnosis by fine needle sampling without aspiration. Cancer 59: 1201-1205